Liraglutide
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
In January 2010, liraglutide (Victoza; Novo Nordisk)--an injectable glucagon-like peptide 1 receptor agonist--was approved by the US FDA to improve glycaemic control in adults with type 2 diabetes mellitus.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The elimination half-life of liraglutide is 13 h, and only one injection per day is required.62”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [62]
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Self-citationGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Marre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 820
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Incretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649
Self-citation
Research works printed but not linked: 2
- Knudsen, L. B. et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 4 Mar 2010 (doi: 10.1210/en.2009–1272) · DOI · Paper page
- Vosser, R. Hauber, A. & Gordon, J. D. Europe Equity Research Report (J. P. Morgan, 5 Feb 2010).
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“60 Liraglutide was subsequently approved for marketing in February 2010, 62 and lixisenatide was approved for marketing in the European Union in 2013 for the treatment of T2DM and in the United States in July 2016.”
Biopharmaceutical benchmarks 2010
Walsh, G. (2010) · Nature Biotechnology · doi:10.1038/nbt0910-917 · Cited by 756
Advances in oral peptide therapeutics
Drucker, D. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0053-0 · Cited by 646
Self-citationBioactive Peptides: Synthesis, Sources, Applications, and Proposed Mechanisms of Action
Akbarian, M., Khani, A., Eghbalpour, S., & Uversky, V. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031445 · Cited by 612
Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514
Self-citationSignaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
Prodrugs in medicinal chemistry and enzyme prodrug therapies
Walther, R., Rautio, J., & Zelikin, A. N. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.013 · Cited by 288
Industrial natural product chemistry for drug discovery and development
Bauer, A., & Brönstrup, M. (2014) · Nat. Prod. Rep. · doi:10.1039/c3np70058e · Cited by 255
Antimicrobial peptides: an alternative for innovative medicines?
da Costa, J. P., Cova, M., Ferreira, R., & Vitorino, R. (2015) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-015-6375-x · Cited by 206
Manandhar, B., & Ahn, J.-M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm500810s · Cited by 198
The central GLP-1: implications for food and drug reward
Skibicka, K. P. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00181 · Cited by 188
Kapitza, C., Nosek, L., Jensen, L., Hartvig, H., Jensen, C. B., & Flint, A. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.443 · Cited by 175
Instability Challenges and Stabilization Strategies of Pharmaceutical Proteins
Akbarian, M., & Chen, S.-H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112533 · Cited by 169
Regulation of Adipocyte Formation by GLP-1/GLP-1R Signaling
Challa, T. D., Beaton, N., Arnold, M., Rudofsky, G., Langhans, W., & Wolfrum, C. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.310342 · Cited by 149
Noda, H., Erős, G., & Bode, J. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5018442 · Cited by 100
Tølbøl, K. S., Kristiansen, M. N., Hansen, H. H., Veidal, S. S., Rigbolt, K. T., Gillum, M. P., Jelsing, J., Vrang, N., & Feigh, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i2.179 · Cited by 134
Unraveling oxyntomodulin, GLP1's enigmatic brother
Pocai, A. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0368 · Cited by 130
Qi, L., Ke, L., Liu, X., Liao, L., Ke, S., Liu, X., Wang, Y., Lin, X., Zhou, Y., Wu, L., et al. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.04.052 · Cited by 136
The Human GLP-1 Analog Liraglutide and the Pancreas
Nyborg, N. C. B., Mølck, A.-M., Madsen, L. W., & Bjerre Knudsen, L. (2012) · Diabetes · doi:10.2337/db11-0936 · Cited by 125
Glucagon-Like-Peptide-1 Receptor Expression in Normal and Diseased Human Thyroid and Pancreas
Waser, B., Blank, A., Karamitopoulou, E., Perren, A., & Reubi, J. C. (2015) · Modern Pathology · doi:10.1038/modpathol.2014.113 · Cited by 119
Glucagon‐like peptide‐1 in the rat brain: Distribution of expression and functional implication
Gu, G., Roland, B., Tomaselli, K., Dolman, C. S., Lowe, C., & Heilig, J. S. (2013) · Journal of Comparative Neurology · doi:10.1002/cne.23282 · Cited by 119
Hayes, M. R., Kanoski, S. E., Alhadeff, A. L., & Grill, H. J. (2011) · Obesity · doi:10.1038/oby.2011.50 · Cited by 110
Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists
Evers, A., Haack, T., Lorenz, M., Bossart, M., Elvert, R., Henkel, B., Stengelin, S., Kurz, M., Glien, M., Dudda, A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00174 · Cited by 101
A Potent α/β-Peptide Analogue of GLP-1 with Prolonged Action in Vivo
Johnson, L. M., Barrick, S., Hager, M. V., McFedries, A., Homan, E. A., Rabaglia, M. E., Keller, M. P., Attie, A. D., Saghatelian, A., Bisello, A., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja507168t · Cited by 96
Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy
Zhang, P., Xu, M., Ding, J., Chen, J., Zhang, T., Huo, L., & Liu, Z. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05591-x · Cited by 96
Wootten, D. L., Simms, J., Koole, C., Woodman, O. L., Summers, R. J., Christopoulos, A., & Sexton, P. M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.176362 · Cited by 90
Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice
Finn, P. D., Rodriguez, D., Kohler, J., Jiang, Z., Wan, S., Blanco, E., King, A. J., Chen, T., Bell, N., Dragoli, D., et al. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00300.2018 · Cited by 81
Ishikawa, Y., Hira, T., Inoue, D., Harada, Y., Hashimoto, H., Fujii, M., Kadowaki, M., & Hara, H. (2015) · Food & Function · doi:10.1039/c4fo01054j · Cited by 80
Kim, B.-J., Zhou, J., Martin, B., Carlson, O. D., Maudsley, S. R., Greig, N. H., Mattson, M. P., Ladenheim, E. E., Wustner, J., Turner, A., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166470 · Cited by 80
Jean, M., Alameh, M., Jesus, D. D., Thibault, M., Lavertu, M., Darras, V., Nelea, M. I., Buschmann, M. D., & Merzouki, A. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.10.029 · Cited by 85
Atrial remodeling and atrial fibrillation in acquired forms of cardiovascular disease
Jansen, H. J., Bohne, L. J., Gillis, A. M., & Rose, R. A. (2020) · Heart Rhythm O2 · doi:10.1016/j.hroo.2020.05.002 · Cited by 74
Reddy, L. H., Urmann, M., Besenius, M., Ulrich, W., Haack, T., Brun, P., Alié, J., Illel, B., Hortala, L., Vogel, R., et al. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.011 · Cited by 77
Basalay, M. V., Davidson, S. M., & Yellon, D. M. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06915-8 · Cited by 68
DPP‐IV‐resistant, long‐acting oxyntomodulin derivatives
Santoprete, A., Capitò, E., Carrington, P. E., Pocai, A., Finotto, M., Langella, A., Ingallinella, P., Zytko, K., Bufali, S., Cianetti, S., et al. (2011) · Journal of Peptide Science · doi:10.1002/psc.1328 · Cited by 65
Kong, F., Wu, J., Sun, S., Ma, L., & Zhou, J. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.001 · Cited by 69
Lipopeptides for Vaccine Development
Hamley, I. W. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00258 · Cited by 62
Bohne, L. J., Jansen, H. J., Dorey, T. W., Daniel, I. M., Jamieson, K. L., Belke, D. D., McRae, M. D., & Rose, R. A. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.01.005 · Cited by 79
Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins
Tan, H., Su, W., Zhang, W., Wang, P., Sattler, M., & Zou, P. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190206105232 · Cited by 64
Yang, X., Qiang, Q., Li, N., Feng, P., Wei, W., & Hölscher, C. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.844697 · Cited by 58
He, Z., Nie, T., Hu, Y., Zhou, Y., Zhu, J., Liu, Z., Liu, L., Leong, K. W., Chen, Y., & Mao, H. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.014 · Cited by 57
Pang, J., Feng, J. N., Ling, W., & Jin, T. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.003 · Cited by 52
Han, J. D. J., Sun, L., Huang, X., Li, Z., Zhang, C., Qian, H., & Huang, W. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12843 · Cited by 54
The Ideal Diabetes Therapy: What Will It Look Like? How Close Are We?
Rotenstein, L. S., Kozak, B. M., Shivers, J. P., Yarchoan, M. M., Close, J., & Close, K. L. (2012) · Clinical Diabetes · doi:10.2337/diaclin.30.2.44 · Cited by 56
A Biomolecular Toolbox for Precision Nanomotors
Yong, J. M., Mellick, A. S., Whitelock, J. M., Wang, J., & Liang, K. (2022) · Advanced Materials · doi:10.1002/adma.202205746 · Cited by 58
Nonogaki, K., Hazama, M., & Satoh, N. (2014) · BioMed Research International · doi:10.1155/2014/751930 · Cited by 50
Regulatory Guidelines for the Analysis of Therapeutic Peptides and Proteins
Elsayed, Y. Y., Kühl, T., & Imhof, D. (2025) · Journal of Peptide Science · doi:10.1002/psc.70001 · Cited by 57
Han, J. D. J., Huang, X., Sun, L., Li, Z., Qian, H., & Huang, W. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.05.012 · Cited by 47
Discovery, biochemical characterization, and bioengineering of cyanobactin prenyltransferases
Zhang, Y., Goto, Y., & Suga, H. (2022) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2022.11.002 · Cited by 45
Li, Y., Wang, Y., Wei, Q., Zheng, X., Tang, L., Kong, D., & Gong, M. (2015) · Scientific Reports · doi:10.1038/srep18039 · Cited by 48
Hu, E.-H., Tsai, M.-L., Lin, Y., Chou, T.-S., & Chen, T.-H. (2024) · Medicina · doi:10.3390/medicina60030357 · Cited by 43
“The second GLP-1 RA to be commercially available was liraglutide, approved in 2009, which was designed to be similar to mammalian GLP-1 [27].”
BackgroundMizuno, A., Cherepanov, S., Kikuchi, Y., Fakhrul, A., Akther, S., Deguchi, K., Yoshihara, T., Ishihara, K., Shuto, S., & Higashida, H. (2015) · Brain Sciences · doi:10.3390/brainsci5010003 · Cited by 43
Patoulias, D., Doumas, M. N., Kotsis, V., Stavropoulos, K., Imprialos, K. P., Zografou, I., Petidis, K., Bakatselos, S., & Karagiannis, A. I. (2020) · Current Diabetes Reviews · doi:10.2174/1573399815666190614141918 · Cited by 53
He, W., Wang, H., Zhao, C., Tian, X., Li, L., & Wang, H. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29204 · Cited by 43
Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands
Tanday, N., Flatt, P. R., & Irwin, N. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15485 · Cited by 41
Elvert, R., Herling, A. W., Bossart, M., Weiss, T., Zhang, B., Wenski, P., Wandschneider, J., Kleutsch, S., Butty, U., Kannt, A., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13212 · Cited by 42
Desai, A., Petrov, J. C., Hashash, J. G., Patel, H. D., Brahmbhatt, B. S., Kochhar, G. S., & Farraye, F. A. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18138 · Cited by 47
Bianchi, E., Carrington, P. E., Ingallinella, P., Finotto, M., Santoprete, A., Petrov, A., Eiermann, G. J., Kosinski, J. R., Marsh, D. J., Pocai, A., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.09.016 · Cited by 45
Functional importance of GLP-1 receptor species and expression levels in cell lines
Knudsen, L. B., Hastrup, S., Underwood, C. R., Wulff, B. S., & Fleckner, J. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2011.12.006 · Cited by 42
Liraglutide, a glucagon-like peptide-1 analog, induce autophagy and senescence in HepG2 cells
Krause, G. C., Lima, K. G., Dias, H. B., da Silva, E. F. G., Haute, G. V., Basso, B. D. S., Gassen, R. B., Marczak, E. S., Nunes, R. S. B., & de Oliveira, J. R. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.015 · Cited by 47
Albumin–Polymer–Drug Conjugates: Long Circulating, High Payload Drug Delivery Vehicles
Autzen, A. A. A., Zuwała, K., Pilgram, O., Johansen, K. S., Tolstrup, M., Dagnæs‐Hansen, F., & Zelikin, A. N. (2016) · ACS Macro Letters · doi:10.1021/acsmacrolett.6b00544 · Cited by 41
Usage of Glucagon-Like Peptide-1 for Obesity in Children; Updated Review of Clinicaltrials.gov
Alorfi, N. M., & Alshehri, F. S. (2023) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s419245 · Cited by 41
Koole, C., Wootten, D. L., Simms, J., Savage, E. E., Miller, L. J., Christopoulos, A., & Sexton, P. M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.309369 · Cited by 42
Morrow, L., Hompesch, M., Guthrie, H., Chang, D., & Chatterjee, D. J. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01322.x · Cited by 38
Venanzi, M., Savioli, M., Cimino, R., Gatto, E., Palleschi, A., Ripani, G., Cicero, D. O., Placidi, E., Orvieto, F., & Bianchi, E. (2020) · Soft Matter · doi:10.1039/d0sm01011a · Cited by 40
Hira, T., Ikee, A., Kishimoto, Y., Kanahori, S., & Hara, H. (2015) · British Journal Of Nutrition · doi:10.1017/s0007114514004322 · Cited by 39
High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats
Mul, J. D., Begg, D. P., Barrera, J. G., Li, B., Matter, E. K., D'Alessio, D. A., Woods, S. C., Seeley, R. J., & Sandoval, D. A. (2013) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00588.2012 · Cited by 37
Ji, Y., Zhao, Z., Cai, T., Yang, P., & Cheng, M. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.1956 · Cited by 37
Lipidization as a tool toward peptide therapeutics
Myšková, A., Sýkora, D., Kuneš, J., & Maletínská, L. (2023) · Drug Delivery · doi:10.1080/10717544.2023.2284685 · Cited by 41
“Semaglutide (Ozempic/Rybelsus or wegovy, Novo Nordisk), is similarly to liraglutide, a GlP-1 receptor agonist with a prolonged plasma half-life (Kalra & Sahay, 2020).”
BackgroundInfluentialChen, T., Reich, N. W., Bell, N., Finn, P. D., Rodriguez, D. J., Kohler, J. N., Kozuka, K., He, L., Spencer, A. G., Charmot, D., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00308 · Cited by 40
Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease
Fu, Y., Zhou, Y., Shen, L., Li, X., Zhang, H., Cui, Y., Zhang, K., Li, W., Chen, W., Zhao, S., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.973366 · Cited by 40
GLP-1 analogs containing disulfide bond exhibited prolonged half-life in vivo than GLP-1
Li, Y., Zheng, X., Tang, L., Xu, W., & Gong, M. (2011) · Peptides · doi:10.1016/j.peptides.2011.04.001 · Cited by 33
Wan, Y., Bao, X., Huang, J., Zhang, X., Liu, W., Cui, Q., Jiang, D., Wang, Z., Liu, R., & Wang, Q. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00294 · Cited by 38
Peptides in Cosmetics: From Pharmaceutical Breakthroughs to Skincare Innovations
Tang, Y., Nie, T., Zhang, L., Liu, X., & Deng, H. (2025) · Cosmetics · doi:10.3390/cosmetics12030107 · Cited by 35
Qi, L., Chen, Z., Wang, Y., Liu, X., Liu, X., Ke, L., Zheng, Z., Lin, X., Zhou, Y., Liu, L., et al. (2017) · Europe PMC (PubMed Central) · Cited by 37
Conjugation with glucagon like peptide-1 enables targeted protein degradation
Zhu, L., Zhou, Y., Zhang, B., Luo, Y., Chen, F., Yan, X., Cai, Y., Jiang, L., & Ge, J. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106908 · Cited by 31
Prolonged Drug-Releasing Fibers Attenuate Alzheimer’s Disease-like Pathogenesis
Salles, G. N., Calió, M. L., Afewerki, S., Soares, C. P., Porcionatto, M. A., Hölscher, C., & Lobo, A. O. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b12649 · Cited by 30
Preparation and Characterization of PEGylated Amylin
Guerreiro, L. H., Guterres, M. F. A. N., Melo-Ferreira, B., Erthal, L. C. S., Rosa, M. D. S., Lourenço, D. C., Tinoco, P., & Lima, L. M. T. R. (2013) · AAPS PharmSciTech · doi:10.1208/s12249-013-9987-4 · Cited by 28
Wang, L., Liu, Y., Yang, J., Zhao, H., Ke, J., Tian, Q., Zhang, L., Wen, J., Wei, R., & Hong, T. (2014) · Endocrinology · doi:10.1210/en.2014-1218 · Cited by 28
Radiolabelled GLP-1 receptor antagonist binds to GLP-1 receptor-expressing human tissues
Waser, B., & Reubi, J. C. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2684-4 · Cited by 29
Singh, A. P., Guo, Y., Baldelli, A., & Singh, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092265 · Cited by 32
Jeon, H., Lee, A.-J., & Ha, K. (2022) · BioChip Journal · doi:10.1007/s13206-022-00057-0 · Cited by 26
Liraglutide Promotes Cortical Neurite Outgrowth via the MEK–ERK Pathway
Li, M., Li, S., & Li, Y. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0193-7 · Cited by 25
Recent developments of automated flow chemistry in pharmaceutical compounds synthesis
Wu, J., Yang, X., Pan, Y., Zuo, T., Ning, Z., Li, C., & Zhang, Z. (2023) · Journal of Flow Chemistry · doi:10.1007/s41981-023-00285-x · Cited by 28
Azevedo, C., Pinto, S., Benjakul, S., Nilsen, J., Santos, H. A., Traverso, G., Andersen, J. T., & Sarmento, B. F. C. C. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.016 · Cited by 29
Sun, C., Trevaskis, J. L., Jodka, C. M., Neravetla, S., Griffin, P., Xu, K., Wang, Y., Parkes, D. G., Forood, B., & Ghosh, S. S. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401418s · Cited by 22
Discovery of Dual-Action Membrane-Anchored Modulators of Incretin Receptors
Fortin, J., Chinnapen, D. J. ‐., Beinborn, M., Lencer, W. I., & Kopin, A. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024693 · Cited by 22
Molecular and Materials Engineering for Delivery of Peptide Drugs to Treat Type 2 Diabetes
Varanko, A. K., & Chilkoti, A. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801509 · Cited by 23
Disulfide bond prolongs the half-life of therapeutic peptide-GLP-1
Li, Y., Li, X., Zheng, X., Tang, L., Xu, W., & Gong, M. (2011) · Peptides · doi:10.1016/j.peptides.2011.05.003 · Cited by 20
Nonogaki, K., Suzuki, M., Sanuki, M., Wakameda, M., & Tamari, T. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.06.175 · Cited by 21
Abdelaziz, A. I., Mantawy, E. M., Gad, A. M., Fawzy, H. M., & Azab, S. S. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.110719 · Cited by 19
Carbajo, D., Fransen, P., El‐Faham, A., Royo, M., & Alberício, F. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b00813 · Cited by 20
Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact
Lee, A. A., Khotina, V. A., Kashirskikh, D. A., Voronko, O. E., Gasanov, V. A. O., & Vasiliev, A. V. (2025) · Medical Sciences · doi:10.3390/medsci13040269 · Cited by 26
Long-Acting GLP-1 Analogue in V-Shaped Conformation by Terminal Polylysine Modifications
Yang, X., Li, Y., Wang, Y., Zheng, X., Kong, W., Meng, F., Zhou, Z., Liu, C., Li, Y., & Gong, M. (2014) · Molecular Pharmaceutics · doi:10.1021/mp5002685 · Cited by 17
Kalogirou, M., Patoulias, D., Haidich, A., Akriviadis, E. A., & Sinakos, E. (2020) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2020.10.012 · Cited by 17
Hyde, K. M., Blonde, G. D., le Roux, C. W., & Spector, A. C. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.03.045 · Cited by 16
Long-Acting, Potent Delivery of Combination Antiretroviral Therapy
Andersen, A. H. F., Frich, C. K., Zuwała, K., Tolstrup, M., Dagnæs‐Hansen, F., Denton, P. W., & Zelikin, A. N. (2018) · ACS Macro Letters · doi:10.1021/acsmacrolett.8b00179 · Cited by 19
Recent update on biological activities and pharmacological actions of liraglutide
Tiwari, J., Gupta, G., Dahiya, R., Pabreja, K., Sharma, R. K., Mishra, A., & Dua, K. (2017) · EXCLI journal · doi:10.17179/excli2017-323 · Cited by 17
He, W., Tian, X., Lv, M., & Wang, H. (2018) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2018.05.039 · Cited by 17
Metadata
- Authors
- Drucker, D. J., Dritselis, A., & Kirkpatrick, P.
- Affiliations
- Mount Sinai Hospital (CA)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2010-04
- Volume
- 9
- Issue
- 4
- Pages
- 267-268
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W4245650535
- Cited by
- 181
- References
- 13
- Citations by year
- 2026: 11 · 2025: 19 · 2024: 13 · 2023: 12 · 2022: 21 · 2021: 9 · 2020: 10 · 2019: 11 · 2018: 8 · 2017: 8 · 2016: 6 · 2015: 8 · 2014: 11 · 2013: 12 · 2012: 6
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- liraglutide, GLP-1 receptor agonists, type 2 diabetes, glycemic control, FDA approval, injectable drugs
- MeSH terms
- Liraglutide, Adult, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, United States, United States Food and Drug Administration, Randomized Controlled Trials as Topic, Drug Approval, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.